Zealand Pharma A/S
ZEAL.CO · CPH
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.19 | -0.00 | -1.78 | -4.68 |
| FCF Yield | -1.38% | 33.93% | -1.40% | -0.36% |
| EV / EBITDA | -76.17 | 2.25 | -111.78 | -184.09 |
| Quality | ||||
| ROIC | -3.25% | 48.45% | -4.61% | -4.36% |
| Gross Margin | 85.43% | 100.00% | 95.00% | 95.49% |
| Cash Conversion Ratio | 1.10 | 1.12 | 1.49 | 0.62 |
| Growth | ||||
| Revenue 3-Year CAGR | 198.71% | 363.19% | -20.21% | -17.36% |
| Free Cash Flow Growth | -105.26% | 1,770.61% | -177.73% | 37.99% |
| Safety | ||||
| Net Debt / EBITDA | 15.79 | -0.84 | 1.18 | 0.32 |
| Interest Coverage | -65.93 | 918.83 | -50.52 | -35.61 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.04 | 0.04 | 0.04 |
| Cash Conversion Cycle | -2,219.03 | -66,284.29 | -50,253.24 | -36,247.02 |